Clinical Trial Update: Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses [Phase 3]

View source ↗

Summary

This Phase 3 trial update reports on the pharmacokinetics, safety and tolerability of miglustat (Zavesca) in infants with GM2 gangliosidosis, including Tay-Sach…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gm2 Gangliosidosis
• Sandhoff Disease
• Tay-sachs Disease

Drugs mentioned

• Zavesca (Miglustat)

Snippet

Sponsor: Children's National Research Institute | Conditions: GM2 Gangliosidoses, Tay-Sachs | Phase 3 | Status: COMPLETED